Avinger Announces Fourth Quarter and Full Year 2017 Results

Avinger (Nasdaq:AVGR) a leading developer of innovative treatments for peripheral artery disease, today reported results for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

“With our recent financing successfully completed, we believe we are on solid footing as we work to achieve a number of important product development and regulatory milestone goals this year,” said Jeff Soinski, Avinger’s president and CEO. “We continue to expect FDA clearance of the next generation Pantheris in the first half of 2018, and we are preparing to initiate a rollout of this significantly improved device to our loyal physician base following clearance.”

Click here to read the full press release.